Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Zimmer Biomet Holdings Inc    ZBH

Delayed Quote. Delayed  - 07/28 10:02:00 pm
127.47 USD   +3.90%
07/28DJZIMMER BIOMET : Boosts Bottom End of Earnings Forecast as Loss Narro..
07/28 ZIMMER BIOMET : reports 2Q loss
07/28 ZIMMER BIOMET : Jul 28, 2016 Zimmer Biomet Reports Second Quarter 20..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Zimmer Holdings, Inc. : Zimmer Receives FDA Warning on Certain Hip Implants

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/02/2012 | 12:40am CEST

--Zimmer says FDA inspection of Puerto Rico plant turned up concerns about manufacturing of certain implants

--FDA in letter noted manufacturing, testing issues related to Trilogy Acetabuar System products, company says

--Zimmer says it is notifying customers of manufacturing issue, but hasn't withdrawn any products

(Adds context on metallic spikes in fourth paragraph and a no comment from Zimmer in seventh paragraph.)

 
   By Kristin Jones 
 

Zimmer Holdings Inc. (ZMH) said a U.S. Food and Drug Administration inspection of its plant in Puerto Rico turned up concerns about the manufacturing of certain hip implants.

The orthopedic maker's Zimmer Inc. subsidiary received a warning letter from the FDA dated Sept. 19, the company said in a regulatory filing Monday. In the letter, the FDA noted manufacturing and testing issues related to the company's Trilogy Acetabular System products, which are implanted in hip-replacement surgery.

Specifically, the U.S. drug regulator noted that Zimmer hadn't implemented a testing mechanism to show that its products met design specifications. The company also hadn't validated the effect of certain manufacturing operations on Trilogy products that incorporate metallic spikes.

Spikes are used to connect the hip replacement cup to a patient's bone when cement and screws are deemed insufficient.

The FDA requires that drug and medical-device makers undertake steps to ensure the quality of the design and manufacture of its products, known as process validation.

Zimmer said it is notifying customers of the manufacturing issue, but that it hasn't withdrawn any products. The company also said it previously suspended release of the spiked products, pending validation of the processes cited in the letter, and expects to complete validation in the next few weeks.

A Zimmer spokesman declined to comment further.

Shares gained 11 cents to $67.98 in after-hours trading. Through Monday's close, the stock was up 27% so far this year.

--Joseph Walker contributed to this article.

Write to Kristin Jones at kristin.jones@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ZIMMER BIOMET HOLDINGS INC
07/28 ZIMMER BIOMET : Announces Multi-Year Collaboration with Indo UK Institutes of He..
07/28DJZIMMER BIOMET : Boosts Bottom End of Earnings Forecast as Loss Narrows
07/28 ZIMMER BIOMET : reports 2Q loss
07/28 ZIMMER BIOMET HOLDINGS, INC. : Results of Operations and Financial Condition, Fi..
07/28 ZIMMER BIOMET : Jul 28, 2016 Zimmer Biomet Reports Second Quarter 2016 Financial..
07/28 Weak China sales drag down Smith & Nephew profits
07/26 ZIMMER BIOMET : Jul 26, 2016 Zimmer Biomet Unveils Signature Solutions™
07/25ZIMMER BIOMET HOLDINGS INC : half-yearly earnings release
07/20DJSt. Jude Medical Logs Double-Digit Sales Growth -- Update
07/20DJSt. Jude Medical Logs Double-Digit Sales Growth
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
07/28 Weak China sales drag down Smith & Nephew profits
07/27DJAlere Faces Criminal Probe Over Medicare, Medicaid Billing
07/26DJBAXTER : Results Boosted by Growth in Hospital Products Segment
07/25DJBAXTER : CFOs Turn to Consultants as Challenges Mount
07/22DJDEXCOM : Shares Rise After FDA Panel Vote
More sector news : Medical Equipment, Supplies & Distribution - NEC
News from SeekingAlpha
07/28 Zimmer Biomet Holdings' (ZBH) CEO David Dvorak on Q2 2016 Results - Earnings ..
07/28 Zimmer Biomet Q2 top line up 66%; non-GAAP net income up 47%; cash flow up 96..
07/28 Zimmer Biomet beats by $0.05, beats on revenue
07/27 Notable earnings before Thursday?s open
07/25 Smith & Nephew Continues To Impress
Advertisement
Financials ($)
Sales 2016 7 626 M
EBIT 2016 2 514 M
Net income 2016 802 M
Debt 2016 9 337 M
Yield 2016 0,72%
P/E ratio 2016 29,83
P/E ratio 2017 19,87
EV / Sales 2016 4,56x
EV / Sales 2017 4,25x
Capitalization 25 453 M
More Financials
Chart ZIMMER BIOMET HOLDINGS INC
Duration : Period :
Zimmer Biomet Holdings Inc Technical Analysis Chart | ZBH | US98956P1021 | 4-Traders
Full-screen chart
Technical analysis trends ZIMMER BIOMET HOL...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 132 $
Spread / Average Target 3,8%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David C. Dvorak President, Chief Executive Officer & Director
Larry C. Glasscock Non-Executive Chairman
Robin T. Barney Senior VP-Global Operations & Logistics
Daniel P. Florin Chief Financial Officer & Senior Vice President
David J. Kunz VP-Global Quality, Clinical & Regulatory Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ZIMMER BIOMET HOLDINGS..24.25%25 453
MEDTRONIC PLC13.65%121 927
BAXTER INTERNATIONAL I..26.40%26 630
C R BARD INC18.38%16 472
TERUMO CORP20.49%16 383
DENTSPLY SIRONA INC3.70%14 780
More Results